| scholarly article | Q13442814 |
| P2093 | author name string | Thomas Walter | |
| Enrique Grande | |||
| Mohid S Khan | |||
| Amy Buchanan-Hughes | |||
| Marion Feuilly | |||
| Emma Worthington | |||
| Lucie Keeber | |||
| P2860 | cites work | Diagnosis and management of intestinal ischaemic disorders | Q24527260 |
| Methods for diagnosis of bile acid malabsorption in clinical practice | Q24618216 | ||
| Current state of knowledge on neuroendocrine small bowel tumours: non-systematic review of the literature based on one case | Q26865730 | ||
| Lanreotide in metastatic enteropancreatic neuroendocrine tumors | Q28243728 | ||
| How to interpret hydrogen breath tests | Q28246206 | ||
| Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease | Q28255314 | ||
| Diagnosis and treatment of pancreatic exocrine insufficiency | Q34386682 | ||
| Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. | Q34400151 | ||
| Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide | Q34428697 | ||
| Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ | Q34491660 | ||
| Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) | Q35760798 | ||
| Regional Gastrointestinal Transit Times in Patients With Carcinoid Diarrhea: Assessment With the Novel 3D-Transit System | Q35834537 | ||
| Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea | Q36103126 | ||
| Radiological Evaluation of Bowel Ischemia | Q36250025 | ||
| Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea | Q36762652 | ||
| Diagnosis of colitis: making the initial diagnosis. | Q36763060 | ||
| Biochemical testing for neuroendocrine tumors | Q37621191 | ||
| Convergent and sequential synthesis designs: implications for conducting and reporting systematic reviews of qualitative and quantitative evidence. | Q37719705 | ||
| The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum | Q37776136 | ||
| New and emerging syndromes due to neuroendocrine tumors | Q37846916 | ||
| Beyond PICO: the SPIDER tool for qualitative evidence synthesis | Q38029299 | ||
| Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy | Q38149681 | ||
| Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Q38257060 | ||
| AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids | Q38472683 | ||
| Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms | Q38573021 | ||
| How to build up the actionable knowledge base: the role of 'best fit' framework synthesis for studies of improvement in healthcare | Q38573675 | ||
| Clinical Presentation and Diagnosis of Neuroendocrine Tumors | Q38650848 | ||
| Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium | Q38707262 | ||
| Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study | Q38753074 | ||
| Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome | Q39165882 | ||
| Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study | Q39176092 | ||
| Potential for Screening for Pancreatic Exocrine Insufficiency Using the Fecal Elastase-1 Test. | Q39185556 | ||
| Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial | Q39194994 | ||
| Synchronous Gastrointestinal Carcinoid Tumor and Colon Adenocarcinoma: Case Reports and Literature Review. | Q39353205 | ||
| Gastrointestinal manifestations of neuroendocrine tumours: their investigation and management | Q39363432 | ||
| Acute diarrhea | Q40218522 | ||
| Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: results from the population-based PROFILES registry | Q41754116 | ||
| Management of the hormonal syndrome of neuroendocrine tumors | Q41832570 | ||
| Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus | Q42289564 | ||
| Chronic octreotide therapy can induce pancreatic insufficiency: a common but under-recognized adverse effect | Q42956376 | ||
| Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas | Q44862801 | ||
| Practical guide to supportive care of patients with functional neuroendocrine tumors | Q45301503 | ||
| Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. | Q45942086 | ||
| Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). | Q46950109 | ||
| Pneumatosis cystoides intestinalis associated with sunitinib and a literature review. | Q47108307 | ||
| Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency - Systematic Review and Meta-analysis. | Q47644783 | ||
| The management of neuroendocrine tumours: A nutritional viewpoint | Q47819836 | ||
| Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. | Q47944297 | ||
| Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study | Q48414772 | ||
| Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population | Q48467742 | ||
| Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial | Q50059510 | ||
| Predictive factors of endocrine and exocrine insufficiency after resection of a benign tumour of the pancreas. | Q51245583 | ||
| Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue. | Q51744981 | ||
| Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic Neuroendocrine tumours. | Q52650398 | ||
| ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. | Q52840482 | ||
| Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. | Q53073936 | ||
| Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. | Q55502689 | ||
| Carcinoid heart disease | Q57108975 | ||
| Pros and Cons of the SeHCAT Test in Bile Acid Diarrhea: A More Appropriate Use of an Old Nuclear Medicine Technique | Q60625155 | ||
| Nutritional and vitamin status in patients with neuroendocrine neoplasms | Q64096444 | ||
| Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome | Q74611871 | ||
| Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study | Q81043263 | ||
| Small-bowel carcinoid with no liver metastases | Q83777653 | ||
| Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study | Q89163198 | ||
| Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines | Q89182961 | ||
| Cases in the Management of GEP-NETs: The Use of Surgery, an Underutilized Option in the Management of Advanced-Stage NETs | Q89413118 | ||
| Prevalence of self-reported side effects in neuroendocrine tumour patients prescribed somatostatin analogues | Q89565270 | ||
| Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues | Q90846728 | ||
| Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs | Q91254023 | ||
| Management of Diarrhea in Patients With Carcinoid Syndrome | Q92697318 | ||
| Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study | Q93197919 | ||
| Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect | Q94673629 | ||
| P433 | issue | 30 | |
| P304 | page(s) | 4537-4556 | |
| P577 | publication date | 2020-08-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review | |
| P478 | volume | 26 |
Search more.